Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

NCT00665314 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Non Hodgkin's Lymphoma
Hodgkin's Disease
Multiple Myeloma

Interventions

DRUG: Plerixafor (AMD3100)
DRUG: Can be any registered nonpegylated form of G-CSF

Sponsor

Genzyme, a Sanofi Company